实用癌症杂志
實用癌癥雜誌
실용암증잡지
THE PRACTICAL JOURNAL OF CANCER
2014年
7期
855-857
,共3页
恩度%顺铂%非小细胞肺癌%HIF-1α%VEGF
恩度%順鉑%非小細胞肺癌%HIF-1α%VEGF
은도%순박%비소세포폐암%HIF-1α%VEGF
Endostar%Cisplatin%Non-small cell lung cancer%HIG-1α%VEGF
目的：观察恩度联合顺铂局部治疗非小细胞肺癌（ NSCLC）合并胸腔积液的疗效及对积液中VEGF、HIF-1的影响。方法选取30例NSCLC合并恶性胸腔积液患者为研究对象，均采用顺铂联合恩度胸腔局部注入治疗，并在治疗前、后抽取患者3 ml胸腔积液，酶联免疫吸附法测定血清VEGF、HIF-1α水平。观察局部化疗的临床效果，分析不同疗效患者VEGF、HIF-1α水平的变化。结果所有患者均完成2周化疗，其中CR 1例，PR 9例，SD 12例，PD 8例，总有效率为33．3％，疾病控制率为73．3％，随访至今，中位缓解时间为65 d （7～354 d）。所有患者对局部灌注化疗耐受性较好，未出现严重不良反应，10例患者生存质量改善。按照临床疗效将30例患者分为有效组（ CR＋PR，10例）和无效组（SD＋PD，20例），化疗后CR＋PR患者胸腔积液中VEGF、HIF-1α水平较化疗前显著降低（P＜0．05），而SD＋PD患者VEGF、HIF-1α水平稍有上升，但差异不明显（ P＞0．05）。结论恩度联合顺铂局部灌注治疗晚期NSCLC合并胸腔积液具有一定的临床效果，不良反应较少，能提高部分患者的生活质量，其作用机制与抑制VEGF、HIF-1α表达水平有关。
目的：觀察恩度聯閤順鉑跼部治療非小細胞肺癌（ NSCLC）閤併胸腔積液的療效及對積液中VEGF、HIF-1的影響。方法選取30例NSCLC閤併噁性胸腔積液患者為研究對象，均採用順鉑聯閤恩度胸腔跼部註入治療，併在治療前、後抽取患者3 ml胸腔積液，酶聯免疫吸附法測定血清VEGF、HIF-1α水平。觀察跼部化療的臨床效果，分析不同療效患者VEGF、HIF-1α水平的變化。結果所有患者均完成2週化療，其中CR 1例，PR 9例，SD 12例，PD 8例，總有效率為33．3％，疾病控製率為73．3％，隨訪至今，中位緩解時間為65 d （7～354 d）。所有患者對跼部灌註化療耐受性較好，未齣現嚴重不良反應，10例患者生存質量改善。按照臨床療效將30例患者分為有效組（ CR＋PR，10例）和無效組（SD＋PD，20例），化療後CR＋PR患者胸腔積液中VEGF、HIF-1α水平較化療前顯著降低（P＜0．05），而SD＋PD患者VEGF、HIF-1α水平稍有上升，但差異不明顯（ P＞0．05）。結論恩度聯閤順鉑跼部灌註治療晚期NSCLC閤併胸腔積液具有一定的臨床效果，不良反應較少，能提高部分患者的生活質量，其作用機製與抑製VEGF、HIF-1α錶達水平有關。
목적：관찰은도연합순박국부치료비소세포폐암（ NSCLC）합병흉강적액적료효급대적액중VEGF、HIF-1적영향。방법선취30례NSCLC합병악성흉강적액환자위연구대상，균채용순박연합은도흉강국부주입치료，병재치료전、후추취환자3 ml흉강적액，매련면역흡부법측정혈청VEGF、HIF-1α수평。관찰국부화료적림상효과，분석불동료효환자VEGF、HIF-1α수평적변화。결과소유환자균완성2주화료，기중CR 1례，PR 9례，SD 12례，PD 8례，총유효솔위33．3％，질병공제솔위73．3％，수방지금，중위완해시간위65 d （7～354 d）。소유환자대국부관주화료내수성교호，미출현엄중불량반응，10례환자생존질량개선。안조림상료효장30례환자분위유효조（ CR＋PR，10례）화무효조（SD＋PD，20례），화료후CR＋PR환자흉강적액중VEGF、HIF-1α수평교화료전현저강저（P＜0．05），이SD＋PD환자VEGF、HIF-1α수평초유상승，단차이불명현（ P＞0．05）。결론은도연합순박국부관주치료만기NSCLC합병흉강적액구유일정적림상효과，불량반응교소，능제고부분환자적생활질량，기작용궤제여억제VEGF、HIF-1α표체수평유관。
Objective To observe the clinical effect of local injection in non-small cell lung cancer ( NSCLC) with ma-lignant pleural effusion and its influence on VEGF and HIG-1α.Methods 30 cases of NSCLC with malignant pleural effusion were selected in our study .All cases were treated with intrapleural injection of endostar combined with DDP ,and extracted 3 ml of pleural effusion pre-treatment and post-treatment.Enzyme linked immunosorbent assay were used to detect the level of serum VEGF and HIG-1α.The clinical effect were recorded ,and the level of serum VEGF and HIG-1αin different clinical effect were observed.Results All patients endured the course of chemotherapy .1 case had CR,9 cases had PR,12 cases had SD and 8 ca-ses had PD.The total effective rate was 33.3%,and the disease control rate was 73.3%.The median remission time were 65 d(7~354 d) .There were no severe side effects ,and all patients had high tolerance to local injection chemotherapy ,10 cases had life quality improved.Based on the clinical effect ,30 cases were divided into effective group ( CR+PR,10 cases) and non-effective group(SD+PD,20 cases).The level of serum VEGF and HIG-1αin effective group were decreased after treatment compared to pre-treatment(P<0.05),the difference had statistical significance .And the level of serum VEGF and HIG-1αhad increased slightly in effective group compared to pre-treatment(P>0.05).Conclusion Intrapleural injection of endostar with DDP in treatment of non-small cell lung cancer with malignant pleural effusion is safe and practicable ,and could enhance the life quality . Its effective mechanism is inhibiting the expression of VEGF and HIG-1α.
